These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33842729)

  • 1. Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors.
    Kadowaki H; Ishida J; Akazawa H; Yagi H; Saga-Kamo A; Umei M; Matsuoka R; Liu Q; Matsunaga H; Maki H; Sato Y; Kume H; Komuro I
    Circ Rep; 2021 Mar; 3(4):234-240. PubMed ID: 33842729
    [No Abstract]   [Full Text] [Related]  

  • 2. Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.
    Waliany S; Sainani KL; Park LS; Zhang CA; Srinivas S; Witteles RM
    JACC CardioOncol; 2019 Sep; 1(1):24-36. PubMed ID: 34396159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma.
    Rini BI; Atkins MB; Choueiri TK; Thomaidou D; Rosbrook B; Thakur M; Hutson TE
    Clin Genitourin Cancer; 2021 Oct; 19(5):e306-e312. PubMed ID: 33947608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs.
    Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
    J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report.
    Yuki H; Kamai T; Kubota K; Abe H; Nishihara D; Mizuno T; Masuda A; Betsunoh H; Yashi M; Fukabori Y; Yoshida K
    Onco Targets Ther; 2014; 7():289-95. PubMed ID: 24627641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
    Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
    Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.
    Hamamoto S; Tasaki Y; Morikawa T; Naiki T; Etani T; Taguchi K; Iwatsuki S; Unno R; Takeda T; Nagai T; Kawase K; Mimura Y; Sugiyama Y; Okada A; Furukawa-Hibi Y; Yasui T
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929893
    [No Abstract]   [Full Text] [Related]  

  • 12. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
    Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
    Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.
    Gunnarsson O; Pfanzelter NR; Cohen RB; Keefe SM
    Cancer Manag Res; 2015; 7():65-73. PubMed ID: 25709499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib in Metastatic Renal Cell Carcinoma.
    Mittal K; Wood LS; Rini BI
    Biol Ther; 2012; 2(1):5. PubMed ID: 24392298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment.
    Juengel E; Schnalke P; Rutz J; Maxeiner S; Chun FK; Blaheta RA
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
    Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
    Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma.
    Tiako Meyo M; Chen J; Goldwasser F; Hirsch L; Huillard O
    Ther Clin Risk Manag; 2022; 18():683-698. PubMed ID: 35837579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.